Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual birch immunotherapy for pollen-associated food allergy
2025-523653-34-00Phase 2Authorised
- Sponsor
- Klinikum rechts der Isar
- Start
- Sep 2026
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of allergenic extract of birch and Lactobacillus rhamnosus GG in Pollen Food Allergy Syndrome (PFAS), birch pollen allergy, allergic rhinitis (AR) and 1 more (2 arms), sponsored by Klinikum rechts der Isar. Primary endpoint: Primary: change in combined global visual analogue scale after apple challenge. Planned start Sep 2026; status: authorised.
02
Drugs
allergenic extract of birchLactobacillus rhamnosus GG
03
Conditions
Pollen Food Allergy Syndrome (PFAS)birch pollen allergyallergic rhinitis (AR)allergic conjunctivitis (AC)
Beyond the preview
Go deeper on 2025-523653-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523653-34-00.